GEMP vs. ELDN, CELU, RPHM, ANVS, IMMX, BLRX, CALC, AEON, CKPT, and GANX
Should you be buying Gemphire Therapeutics stock or one of its competitors? The main competitors of Gemphire Therapeutics include Eledon Pharmaceuticals (ELDN), Celularity (CELU), Reneo Pharmaceuticals (RPHM), Annovis Bio (ANVS), Immix Biopharma (IMMX), BioLineRx (BLRX), CalciMedica (CALC), AEON Biopharma (AEON), Checkpoint Therapeutics (CKPT), and Gain Therapeutics (GANX). These companies are all part of the "medical" sector.
Eledon Pharmaceuticals (NASDAQ:ELDN) and Gemphire Therapeutics (NASDAQ:GEMP) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, community ranking, profitability and dividends.
In the previous week, Eledon Pharmaceuticals had 14 more articles in the media than Gemphire Therapeutics. MarketBeat recorded 14 mentions for Eledon Pharmaceuticals and 0 mentions for Gemphire Therapeutics. Gemphire Therapeutics' average media sentiment score of 0.61 beat Eledon Pharmaceuticals' score of 0.00 indicating that Eledon Pharmaceuticals is being referred to more favorably in the media.
Gemphire Therapeutics received 264 more outperform votes than Eledon Pharmaceuticals when rated by MarketBeat users. However, 71.43% of users gave Eledon Pharmaceuticals an outperform vote while only 69.98% of users gave Gemphire Therapeutics an outperform vote.
56.8% of Eledon Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.5% of Gemphire Therapeutics shares are owned by institutional investors. 19.4% of Eledon Pharmaceuticals shares are owned by insiders. Comparatively, 22.7% of Gemphire Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Eledon Pharmaceuticals has a beta of 0.86, suggesting that its stock price is 14% less volatile than the S&P 500. Comparatively, Gemphire Therapeutics has a beta of 2.82, suggesting that its stock price is 182% more volatile than the S&P 500.
Eledon Pharmaceuticals currently has a consensus target price of $11.67, suggesting a potential upside of 386.11%. Given Gemphire Therapeutics' higher possible upside, equities analysts clearly believe Eledon Pharmaceuticals is more favorable than Gemphire Therapeutics.
Gemphire Therapeutics' return on equity of -46.15% beat Eledon Pharmaceuticals' return on equity.
Summary
Eledon Pharmaceuticals beats Gemphire Therapeutics on 8 of the 12 factors compared between the two stocks.
Get Gemphire Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for GEMP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GEMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Gemphire Therapeutics Competitors List
Related Companies and Tools
